Senores Pharmaceuticals Quarterly Results for Trading Insights

In Sept 2025, Senores Pharmaceuticals (SENORES) reported revenue ₹159 Cr and net profit ₹30 Cr — revenue +59.0% YoY. For annual financials, live price and key ratios, visit Senores Pharmaceuticals stock price NSE .

Latest Quarter Net Profit
₹30 Cr
QSept 2025
Quarterly Results

SENORES Quarterly Results — Revenue, Profit & EPS Highlights

Senores Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with SENORES DCF to assess whether the stock is under or overvalued.

  • Revenue of ₹159 Cr in Sept 2025 (+35.9% vs Mar 2025, +59.0% vs Sept 2024)
  • Net Profit of ₹30 Cr in Sept 2025 (+66.7% vs Mar 2025, +130.8% vs Sept 2024)
  • EBITDA of ₹47 Cr in Sept 2025 (+113.6% vs Mar 2025)
  • Operating Margin of 27.0% in Sept 2025 (+17.0pp vs Mar 2025)
  • Earnings Per Share of ₹6.54 in Sept 2025 (+71.7% vs Mar 2025)

Senores Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS

SENORES quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 QoQ YoY
Revenue (₹ Cr) 159 117 134 169 100 35.9% 59.0%
Net Profit (₹ Cr) 30 18 21 34 13 - -
EBITDA (₹ Cr) 47 22 30 48 23 - -
EPS (₹) 6.54 3.81 4.60 7.29 3.92 - -
Operating Margin (%) 27.0% 10.0% 20.0% 27.0% 21.0% - -

SENORES Share Price Trend — 1-Year Movement Across Quarterly Results

Senores Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Analyse SENORES institutional holdings to track promoter, FII and institutional holdings.

Profitability Ratios

Profit Margin 18.9%
EBITDA Margin 29.6%
Operating Margin 27.0%
ROE (Annual) 14.8%

Balance Sheet Highlights

Total Assets ₹1,227 Cr
Total Equity ₹812 Cr
Current Assets ₹722 Cr
Current Liabilities ₹174 Cr

Cash Flow Analysis

Operating Cash Flow ₹-46 Cr
Investing Cash Flow ₹-430 Cr
Financing Cash Flow ₹573 Cr
Net Cash Flow ₹98 Cr

Current Market Data

Current Price ₹903.50
Exchange NSE
Last Updated Apr 29, 2026

Revenue Trend (₹ Cr)

Dec 2025 169
Jun 2025 134
Mar 2025 117
Sept 2025 159

Net Profit Trend (₹ Cr)

Dec 2025 34
Jun 2025 21
Mar 2025 18
Sept 2025 30

Operating Margin Trend (%)

Dec 2025 27.0%
Jun 2025 20.0%
Mar 2025 10.0%
Sept 2025 27.0%

SENORES vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Senores Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Sept 2025 		₹415,924.72 Cr 1778.7 14,875 3,125 +10.8% - 21.0% 136.8
Divis Laboratories
Sept 2025 		₹171,625.44 Cr 6534.0 2,860 689 +7.1% - 24.1% 251.6
Torrent Pharmaceuti…
Sept 2025 		₹139,344.76 Cr 4231.5 3,219 591 +11.3% - 18.4% 241.2
Dr Reddys Laborator…
Sept 2025 		₹109,930.83 Cr 1329.8 9,135 1,337 +1.1% - 14.6% 82.2
Lupin
Sept 2025 		₹104,941.69 Cr 2311.4 6,921 1,485 +23.2% - 21.5% 71.4
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores